Biotech Startups

SpacePharma develops pharmaceutical research and manufacturing systems designed to operate in microgravity environments aboard satellites and spacecraft. The company uses space-based platforms to conduct drug crystallization, organ-on-chip testing, and other biomedical research that benefits from microgravity conditions.

1 investor

One-time gene therapy products including a candidate for RPE65-related blindness. (NASDAQ: ONCE) (Acquired by Roche)

1 investor

Spartan Bioscience develops rapid, on-site DNA testing platforms designed for in-field diagnostic applications. The Canadian biotechnology company specializes in sample-to-result testing technology for infectious disease and molecular diagnostics.

1 investor

1 investor

The Danforth Technology Company (DTC) is a subsidiary of the Donald Danforth Plant Science Center that helps commercialize plant-science technologies developed by Danforth Center scientists. It supports early-stage startup formation through intellectual property development, licensing, seed funding, and early management, connecting scientists with entrepreneurs and investors.

1 investor

Specie Bio operates BioExchange, an AI-driven platform for finding, matching, and accessing biospecimens and multimodal clinical data from a global network of biobanks, hospitals, clinics, and non-profit institutions. It serves researchers across the R&D lifecycle for uses such as biomarker discovery, diagnostic test development, and training foundation models, with deep oncology and broad disease coverage.

1 investor

bioMérieux develops in vitro diagnostic solutions for clinical laboratories and healthcare teams, covering areas such as antimicrobial stewardship, sepsis detection, respiratory infections, and COVID-19. It also provides diagnostics for food safety and quality and pharmaceutical quality control.

1 investor

Specific Biologics develops in vivo genome editing therapeutics based on its Dualase editors, which use a two-site mechanism to remove, repair, or insert DNA sequences, with an initial focus on correcting expanded DNA repeats. Its pipeline targets CNS, lung, and liver genetic diseases using single AAV or lipid nanoparticle/polymer-encapsulated all-RNA delivery.

1 investor

AI medical diagnostics company whose DeepView imaging platform predicts whether burns and other wounds will heal.

1 investor

SpectronRx develops and manufactures theranostic and diagnostic molecular isotope products (radiopharmaceuticals), operating research and production facilities including cyclotron sites. The company serves the nuclear medicine market and is headquartered in the central US, with facilities in Fishers and South Bend, Indiana.

1 investor

SpeeDx develops PCR-based diagnostic tests for sexually transmitted infections that detect pathogens and antibiotic resistance markers, enabling clinicians to make informed treatment decisions. The tests are designed for use with standard laboratory equipment in clinical settings.

1 investor

Speratum Biopharma develops RNA interference (RNAi) therapeutics for cancer and other hard-to-treat genetic diseases, using its proprietary NoPass RNAi design platform and Nano-In nanoparticle delivery system. Its lead candidate, NM-198, is based on the tumor-suppressor microRNA miR-198 and targets multiple oncogenic pathways in solid tumors.

1 investor

Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps. The company's lead program, SP001, is a novel anti-CD40L monoclonal antibody being advanced in IgG4-related disease and other immune-related conditions.

1 investor

SphereBio develops individualized cancer immunotherapies using engineered biological vesicles (OncoSpheres™) that capture a patient's own tumor antigens and deliver them into immune cells to train the immune system against cancer. The company combines biotechnology, synthetic virology, and AI to create individualized cancer vaccines manufactured without sequencing in under seven days.

1 investor

Spherix Global Insights provides independent syndicated market research and intelligence for pharmaceutical and biotech companies, combining primary research across physicians, patients, and payers with therapeutic expertise and AI-assisted execution. Its data supports commercial decisions and is used in investor reviews and board conversations.

1 investor

Spiber develops next-generation biomaterials based on structural protein technology, producing polymers through fermentation for applications across lifestyle, beauty, food, and healthcare products. The Japanese company operates a production plant in Thailand and a materials sales branch in Europe.

1 investor

Spidfier makes a self-contained lab-in-a-box that identifies fish species through automated DNA sequencing. Seafood producers and regulatory bodies use it to confirm what a product actually contains in minutes rather than days, supporting fraud detection and reduced waste.

1 investor

Developing non-surgical, non-opioid therapies for degenerative disc disease through targeted peptide injection.

1 investor

SPINRAZA is a prescription treatment for spinal muscular atrophy (SMA) that is delivered directly into the cerebrospinal fluid around the spinal cord to reach target tissues. It is aimed at patients diagnosed with SMA and has been studied in an extended clinical trial program.

1 investor

Spintex, a 2018 University of Oxford spinout, develops bioinspired spinning technology and silk-based materials for sustainable and technical textiles. The company draws on silk and polymer science to create fiber materials.

1 investor

Spirovant is a gene therapy company developing treatments for cystic fibrosis and other respiratory diseases, including viral vector-based therapies for airway epithelia. It is based in Philadelphia's Life Sciences Corridor.

1 investor

Spirrow Therapeutics develops a first-in-kind polymer lung surfactant (PLS) based on nanotechnology to treat acute respiratory distress syndrome (ARDS), with a focus on restoring lung function in infants. The therapy is designed to reduce alveolar surface tension and fluid accumulation in the lungs.

1 investor

SpliSense develops antisense oligonucleotides (ASOs) — small synthetic RNA-binding molecules — designed using proprietary algorithms for therapeutic applications including splicing modulation and gene silencing. The company focuses on inhaled ASOs delivered directly to the lungs for treating pulmonary and obstructive lung diseases with minimal systemic exposure.

1 investor

SPMED provides pharmacogenomics testing services and personalized drug therapy solutions, along with drug development and bioanalytical services for custom therapeutics.

1 investor